Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 16/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 8/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 1.00 |
| ▸ | CDK2 | P24941 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.70 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.70 |
| ▸ | CDK7 | P50613 | 1/20 | 0.70 |
| ▸ | CCNH | P51946 | 1/20 | 0.70 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754120 | 1.00 | CDK1 (1.00) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL21316709 | 0.90 | CDK1 (0.81) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL7041292 | 0.85 | CDK1 (1.00) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL21011261 | 0.84 | CDK1 (0.70) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL22789735 | 0.83 | CDK2 (1.00) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL4382069 | 0.82 | CDK1 (1.00) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL6016512 | 0.82 | CDK1 (0.78) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL3851604 | 0.81 | TDP1 (0.78) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL1400442 | 0.81 | CDK1 (1.00) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL20097149 | 0.80 | CCNB2 (1.00) | CDK1CCNB1CCNB2CCNB3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20240316014-A1 | METHOD FOR TREATING DEMYELINATING CONDITIONS | ACADEMIA SINICA (TW) | 2024-09-26 | — | — | US | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | CDK1 3088/4885CCNB1 3767/4885CCNB2 4138/4885 |
| US-20240316014-A1 | METHOD FOR TREATING DEMYELINATING CONDITIONS | CDK5, PMP22, MYT1 | CDK1 8/4885CCNB1 113/4885CCNB2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.